These include, PD-L1 in NSCLC and advanced urothelial carcinoma patients treated with pembrolizumab (130, 131), tumor mutation burden (132), and MSI-H/dMMR in patients with pembrolizumab for unresectable or metastatic mismatch-repair deficient solid tumors (133). Here, CD274 is linked to non-small cell lung carcinoma.